EGFR and neoplasm: VEGF-EGFR crosstalk is well described; however, drug-drug interactions in Gef/H-dot and Gen/H-dot treatments need further investigation and extensive clinical studies in order to maximize the anti-tumor efficacy and minimize target drug resistance and risk of tumor relapse.